Core Laboratories stock faces flat Q4 outlook after Q3 rebound

Published on 11/09/2026 at 03:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Core Laboratories stock enters the fourth quarter after sequential revenue growth but weaker year-over-year earnings. Management sees a broadly flat outlook.

Core Lab weighs recovery against disruption

Third-quarter revenue rose sequentially but declined year over year, while adjusted earnings also remained below the prior-year level.
Reservoir Description and Production Enhancement both grew from the second quarter, although geopolitical disruption and project delays continued to pressure operations.
Management expects fourth-quarter revenue to remain broadly flat and has set a diluted earnings range of 12 to 20 cents per share.

CLB, US21867A1051, Illustration mit AI erstellt.

Core Laboratories reported sequential growth in both operating segments for the third quarter ended September 30, 2026, but earnings remained below the prior-year level. The results and outlook were published by StockTitan on October 28.

Sequential recovery meets a weaker base

Revenue reached 132.077 million United States dollars, up 6.0 percent from the second quarter but down 1.8 percent from the year-earlier quarter. GAAP operating income was 12.065 million United States dollars, down 42.3 percent year over year, while diluted earnings per share attributable to Core Laboratories fell to 0.12 United States dollars from 0.30 United States dollars.

Excluding specific items, operating income was 12.613 million United States dollars and adjusted diluted earnings per share was 0.16 United States dollars. Core Laboratories said the adjusted figures benefited from the sequential recovery, but remained below the prior-year quarter. Free cash flow was 1.723 million United States dollars.

Segments improve as risks persist

Reservoir Description revenue rose 7.1 percent sequentially to 84.318 million United States dollars, while Production Enhancement revenue increased 4.1 percent to 47.759 million United States dollars. Reservoir Description still faced weaker demand for assay services in the Middle East, while delays to diagnostic projects affected Production Enhancement activity in the Gulf of America.

For the fourth quarter, management expects revenue between 128.5 million and 134.5 million United States dollars and diluted earnings per share between 0.12 and 0.20 United States dollars. The guidance assumes a 25 percent effective tax rate and excludes foreign-exchange gains and losses. The company also approved a quarterly dividend of 0.01 United States dollars per share, payable November 30 to shareholders of record on November 9.

Core Lab's business profile

Core Laboratories provides reservoir description and production enhancement services and products for the oil and gas industry. Its activities include laboratory analysis, reservoir evaluation, completion diagnostics, production optimization, fluid inspection and laboratory instrumentation. The company operates a global laboratory network spanning more than 50 countries and also supports carbon capture and storage evaluation.

Core Laboratories stock had a last quote of 8.00 euros on Tradegate at 22:00 CET on Friday, November 6, 2026. The Tradegate page labels the quote as indicative and states that the security is only traded in France; no Xetra comparison is used here.

Current market developments can be followed through the S&P 500 market page.

More news and analyses on Core Laboratories stock are available on the topic page.